Key Role of DAMP in Inflammation, Cancer, and Tissue Repair
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Singer, A. J., & Clark, R. A. F. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411006 · Cited by 6,106
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221 · cited 1×
“Originally, DAMP was associated only with cell death; however, later it was shown that HMGB1 is also secreted by damaged cells.(6) Mechanisms of HMGB1 secretion are elusive, but it has been demonstrated nacht domain leucin-rich repeat PYD containing protein 3 (NLRP-3) inflammasome is associated with HMGB1 secretion.”
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768
HMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437 · cited 2×
“Anti-HMGB1 antibodies confer significant protection against damage in sterile inflammation and infection-induced conditions.(78) HMGB1 is a therapeutic target for inflammation.”
HMGB1 and RAGE in Inflammation and Cancer
Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., & Coyle, A. J. (2010) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132603 · Cited by 1,436
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al. (2000) · Nature · doi:10.1038/35012626 · Cited by 1,217
Fantin, A., Vieira, J. M., Gestri, G., Denti, L., Schwarz, Q., Prykhozhij, S., Peri, F., Wilson, S. W., & Ruhrberg, C. (2010) · Blood · doi:10.1182/blood-2009-12-257832 · Cited by 1,153 · cited 1×
“HMGB1 could also trigger angiogenesis by acting directly as a proangiogenic cytokine and activating endothelial cells,(106,107) or it could promote the secretion of other proangiogenic cytokines, such as VEGF, tumor necrosis factor α, and IL-8,(107) from endothelial cells and macrophages.(108,109)”
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800 · cited 1×
“ATP could be released passively during necrosis, actively under stress, and by dying cancer cells through the Golgi system.(90,91) In the extracellular environment, ATP has a short life due to its enzymatic conversion.”
Cited by
Pattern recognition receptors in health and diseases
Li, D., & Wu, M. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00687-0 · Cited by 1,787
Ferroptosis: a cell death connecting oxidative stress, inflammation and cardiovascular diseases
Yu, Y., Yan, Y., Niu, F., Wang, Y., Chen, X., Su, G., Liu, Y., Zhao, X., Qian, L., Liu, P., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00579-w · Cited by 776
The senescence-associated secretory phenotype and its regulation
Lopes-Paciencia, S., Saint-Germain, E., Rowell, M.-C., Ruiz, A. F., Kalegari, P., & Ferbeyre, G. (2019) · Cytokine · doi:10.1016/j.cyto.2019.01.013 · Cited by 601
Cytokine storm induced by SARS-CoV-2
Song, P., Li, W., Xie, J., Hou, Y., & You, C. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.06.017 · Cited by 537
DAMPs and DAMP-sensing receptors in inflammation and diseases
Ma, M., Jiang, W., & Zhou, R. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.002 · Cited by 515
GPX4, ferroptosis, and diseases
Zhang, W., Liu, Y., Liao, Y., Zhu, C., & Zou, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116512 · Cited by 426
Kitai, Y., Kawasaki, T., Sueyoshi, T., Kobiyama, K., Ishii, K. J., Zou, J., Akira, S., Matsuda, T., & Kawai, T. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601694 · Cited by 318
Demaria, S., Guha, C., Schoenfeld, J., Morris, Z., Monjazeb, A., Sikora, A., Crittenden, M., Shiao, S., Khleif, S., Gupta, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002038 · Cited by 301
Interleukin-6 in Rheumatoid Arthritis
Pandolfi, F., Franza, L., Carusi, V., Altamura, S., Andriollo, G., & Nucera, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155238 · Cited by 278
Self-citationSurgical trauma‐induced immunosuppression in cancer: Recent advances and the potential therapies
Tang, F., Tie, Y., Tu, C., & Wei, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.24 · Cited by 206
Colangelo, M. T., Belletti, S., Govoni, P., Guizzardi, S., & Galli, C. (2021) · Applied Sciences · doi:10.3390/app11104405 · Cited by 28
Metadata
- Authors
- Pandolfi, F., Altamura, S., Frosali, S., & Conti, P.
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 38
- Issue
- 5
- Pages
- 1017-1028
- ISSN
- 0149-2918 (ISSN-L)
- OpenAlex
- W2307082245
- Cited by
- 189
- References
- 15
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.